Your browser doesn't support javascript.
COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data.
Hernandez, Inmaculada; He, Meiqi; Guo, Jingchuan; Tadrous, Mina; Gabriel, Nico; Swabe, Gretchen; Gellad, Walid F; Essien, Utibe R; Saba, Samir; Benjamin, Emelia J; Magnani, Jared W.
  • Hernandez I; Division of Clinical Pharmacy, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, United States of America.
  • He M; Division of Clinical Pharmacy, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, United States of America.
  • Guo J; Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, United States of America.
  • Tadrous M; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
  • Gabriel N; Division of Clinical Pharmacy, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, United States of America.
  • Swabe G; Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
  • Gellad WF; Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System Pittsburgh, Pennsylvania, United States of America.
  • Essien UR; Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System Pittsburgh, Pennsylvania, United States of America.
  • Saba S; Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
  • Benjamin EJ; Department of Medicine, Boston Medical Center and Boston University Department of Medicine, Chobanian and Avedisian School of Medicine, and Department of Epidemiology, School of Public Health, Boston, Massachusetts, United States of America.
  • Magnani JW; Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
PLoS One ; 18(2): e0281068, 2023.
Article in English | MEDLINE | ID: covidwho-2224474
ABSTRACT

BACKGROUND:

Atrial fibrillation (AF) is associated with a five-fold increased risk of stroke and a two-fold increased risk of death. We aimed to quantify changes in new diagnoses of AF following the onset of the COVID-19 pandemic. Investigating changes in new diagnoses of AF is of relevance because delayed diagnosis interferes with timely treatment to prevent stroke, heart failure, and death.

METHODS:

Using De-identified Optum's Clinformatics® Data Mart, we identified 19,500,401 beneficiaries continuously enrolled for 12 months in 2016-Q3 2020 with no history of AF. The primary outcome was new AF diagnoses per 30-day interval. Secondary outcomes included AF diagnosis in the inpatient setting, AF diagnosis in the outpatient setting, and ischemic stroke as initial manifestation of AF. We constructed seasonal autoregressive integrated moving average models to quantify changes in new AF diagnoses after the onset of the COVID-19 pandemic (3/11/2020, date of pandemic declaration). We tested whether changes in the new AF diagnoses differed by race and ethnicity.

RESULTS:

The average age of study participants was 51.0±18.5 years, and 52% of the sample was female. During the study period, 2.7% of the study sample had newly-diagnosed AF. New AF diagnoses decreased by 35% (95% CI, 21%-48%) after the onset of the COVID-19 pandemic, from 1.14 per 1000 individuals (95% CI, 1.05-1.24) to 0.74 per 1000 (95% CI, 0.64 to 0.83, p-value<0.001). New AF diagnoses decreased by 37% (95% CI, 13%- 55%) in the outpatient setting and by 29% (95% CI, 14%-43%) in the inpatient setting. The decrease in new AF diagnoses was similar across racial and ethnic subgroups.

CONCLUSION:

In a nationwide cohort of 19.5 million individuals, new diagnoses of AF decreased substantially following the onset of the COVID-19 pandemic. Our findings evidence pandemic disruptions in access to care for AF, which are concerning because delayed diagnosis interferes with timely treatment to prevent complications.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Atrial Fibrillation / Stroke / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Middle aged Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2023 Document Type: Article Affiliation country: Journal.pone.0281068

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Atrial Fibrillation / Stroke / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Middle aged Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2023 Document Type: Article Affiliation country: Journal.pone.0281068